Onco Wiki / drapeau rouge

La radiothérapie est contre-indiquée ou refusée pour le BLPN au stade précoce (prédomination des lymphocytes nodulaires...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-NLPBL-RT-CONTRAINDICATED
TypeSignal d’alerte
Étatreviewed 2026-05-08 | pending_clinical_signoff
MaladiesDIS-NLPBL
SourcesSRC-NCCN-BCELL-2025

Origine du drapeau rouge

DéfinitionRadiotherapy contraindicated or declined for early-stage NLPBL (nodular lymphocyte-predominant B-cell lymphoma, WHO 5th ed). Major clinical scenarios: (1) Young patient with breast or thyroid field overlap — cumulative RT dose risk of secondary malignancy and cardiac toxicity unacceptable; (2) Prior RT to the involved or adjacent region — reirradiation risks exceed benefit; (3) Patient refuses RT after informed discussion. In all scenarios rituximab monotherapy (4–8 × R weekly) achieves ~94% ORR with ≥70% CR in early-stage NLPBL (Advani 2014, IELSG-37 data) and is the accepted standard alternative. RT remains the default for eligible patients where field is safe and patient consents (stage IA-IIA, ≤2 cm).
Direction cliniquedésescalade
Catégorieaptitude physique
Algorithme de décalageALGO-NLPBL-1L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "rt_contraindicated",
      "value": true
    },
    {
      "finding": "radiotherapy_contraindicated",
      "value": true
    },
    {
      "finding": "prior_rt_to_field",
      "value": true
    },
    {
      "finding": "prior_radiotherapy_adjacent_field",
      "value": true
    },
    {
      "finding": "breast_field_rt_overlap",
      "value": true
    },
    {
      "finding": "thyroid_field_rt_overlap",
      "value": true
    },
    {
      "finding": "patient_refuses_radiotherapy",
      "value": true
    },
    {
      "finding": "rt_patient_preference",
      "value": "declined"
    }
  ],
  "type": "treatment_contraindication"
}

Notes

Only applies after step 1 confirms early-stage (IA-IIA) disease — advanced NLPBL routes to R-CHOP at step 1 before this RF fires. RT-field safety is a nuanced clinical judgment: 'breast field overlap' applies most to left-axillary or mediastinal-adjacent presentations in premenopausal women; thyroid overlap relevant for high cervical/upper mediastinal nodes. MDT coordination with radiation oncology to assess field feasibility is recommended before classifying RT as contraindicated. Note: NLPBL differs from classic Hodgkin lymphoma — ABVD is NOT appropriate (CD20+ B-cell; rituximab is the active backbone). IELSG-37 RCT (rituximab mono vs ISRT vs observation for very-favorable NLPBL) provides the comparative evidence base; pending mature OS data. Draft pending two-reviewer clinical co-lead signoff (CHARTER §6.1).

Utilisé par

Algorithmes